Please login to the form below

Not currently logged in
Email:
Password:

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

Belgium biopharmaceutical company Ablynx has appointed Dr Robert Zeldin to replace Dr Dominique Tersago as its chief medical officer.

A clinical immunologist, Zeldin has more than 15 years combined regulatory and industry experience, having previously served at Merck & Co, Novartis and the FDA.

He has held senior level clinical development positions within pharma and prior to his move into the industry, Zeldin spent several years in private practice and two years as a medical officer at the FDA's Center for Biologics Evaluation and Research.

Ablynx CEO Dr Edwin Moses said: “We are very pleased that someone with Robert's track record and experience is joining Ablynx as chief medical officer.

“Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.”

3rd December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...